Navigation Links
From the clinics to the bench and back -- phenytoin as a mood stabilizer?
Date:3/29/2010

This release is available in Chinese.

Phenytoin is a well known antiepileptic agent widely used throughout the world. Recent clinical studies in patients with bipolar disorder have suggested that, as for other anticonvulsant drugs commonly used in the treatment of bipolar patients including valproate and carbamazepine, phenytoin may have mood-stabilizing effects in addition to its well-known anticonvulsant properties. In a study published in the March 2010 issue of Experimental Biology and Medicine Veronica Mariotti and colleagues utilized DNA microarrays to investigate the molecular underpinnings of the potential mood-stabilizing action of phenytoin by looking at its effect on gene expression in the rat brain.

As compared with untreated animals, rats treated for a month with phenytoin had 508 differentially expressed genes in the hippocampus and 62 in the frontal cortex, including genes involved in GABAergic and glutamatergic neurotransmission, neuroprotection and other genes thought to be crucial for mood regulation. Furthermore, some of these same genes have been shown to be modulated by classical mood-stabilizer agents, like lithium and valproate.

Thus, the findings of this study indicate that chronic phenytoin administration modulates the expression of genes involved in mood regulation and genes that are targets of established mood stabilizers. Dr Mariotti noted that "The results of this study provide preliminary insights into possible molecular mechanisms of action of phenytoin as a potential mood stabilizer and, more in general, the pathophysiology of bipolar disorders".

The study is the product of a fruitful collaboration between the Molecular Biology Laboratory of Dr. Silvia Pellegrini at the Department of Experimental Pathology, University of Pisa Medical School, Pisa, Italy and the Laboratory of Professors Galila Agam and R.H. Belmaker at the Psychiatry Research Unit at the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "Mariotti and colleagues have provided very interesting results on the changes in gene expression in rats treated with phenytoin. There findings shed significant light on the mood altering effects of this antiepileptic drug".


'/>"/>

Contact: Dr. Silvia Pellegrini
silvia.pellegrini@bioclinica.unipi.it
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong
2. UC Davis bench-to-bedside research: Promising treatment in clinical trials
3. Animal models that help translate regenerative therapies from bench to bedside
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the leading ... The Prince,s Trust to uncover insights to support its ... Trust. The UK,s leading youth charity will be using ... results and get a better understanding of the topics and issues ... ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the launch of ... on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO Summit ... peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a unique set ...
(Date:3/22/2017)... Milwaukee, WI (PRWEB) , ... March 22, 2017 , ... ... federal scientific research agencies as outlined in the Administration’s recently published fiscal year 2018 ... for the National Institutes of Health (NIH) by $5.8 billion or roughly 20% of ...
(Date:3/22/2017)... , March 22, 2017  Personal Genome ... its cancer testing contract with the U.S. Department ... tumor profiling assay with the company,s new CancerSELECT ... comprehensive, clinically actionable pan-cancer profiling test that includes ... assess potential patient response to checkpoint inhibitor immunotherapies. ...
(Date:3/20/2017)... ... , ... SSCI and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, are ... the Parenteral Drug Association (PDA), the New York Interphex Show will open on March ... more than 625 exhibitors, the educational and networking opportunities are extremely valuable. INTERPHEX is ...
Breaking Biology Technology: